We previously reported HIV-1 infection in Warao Amerindians from Venezuela. The aim of this study was to evaluate the extent and the dynamic of HIV-1 dissemination in eight Warao communities.
HIV-1 infection was evaluated in 576 Warao Amerindians from the Orinoco Delta. Partial HIV-1 pol sequences were analyzed to reconstruct the spatiotemporal and demographic dynamics of the epidemic.
HIV-1 antibodies were present in 9.55% of Warao Amerindians, ranging from 0 to 22%. A significantly higher prevalence was found in men (15.6%) compared with women (2.6%), reaching up to 35% in men from one community. All but one isolates were classified as subtype B. Warao's HIV-1 subtype-B epidemic resulted from a single viral introduction at around the early 2000s. After an initial phase of slow growth, the subtype B started to spread at a fast rate (0.8/year) following two major routes of migration within the communities.
A dramatic high prevalence was documented in almost all the communities of Warao Amerindians from the Orinoco Delta tested for HIV-1 infection. This epidemic resulted from the dissemination of a single HIV-1 subtype B founder strain introduced about 10 years ago and its size is probably doubling every year, creating a situation that can be devastating for this vulnerable Amerindian group.
Supplemental Digital Content is available in the text
aDirección Regional de Salud Estado Delta Amacuro, Tucupita, Venezuela
bLovelace Respiratory Research Institute, Albuquerque, New Mexico, USA
cLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz – FIOCRUZ, Rio de Janeiro, Brazil
dLaboratorio de Tuberculosis, Instituto de Biomedicina
eLaboratorio de Virología Molecular, Instituto Venezolano de Investigaciones Científicas Caracas, Venezuela.
*Lovelace Respiratory Research Institute, Albuquerque, USA.
Correspondence to Dr Flor H. Pujol, Laboratorio de Virología Molecular, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas, Apdo 20632, Caracas 1020-A, Venezuela. Tel: +58 212 5041623; fax: +58 212 5041623; e-mail: email@example.com
Received 2 December, 2012
Revised 31 January, 2013
Accepted 12 February, 2013
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).